ALSO NOTED: NPS sells drug rights; Pharmacopeia snares milestone; Novartis submits Galvus protocol; and much more...

> NPS Pharmaceuticals has sold the rights to the European sales of a hormone therapy for up to $75 million. Release

> Pharmacopeia will pocket a $500,000 milestone following GSK's move to identify a lead compound for advancement in their collaboration. Release

> Novartis has submitted a protocol to the FDA for an additional trial on the diabetes drug Galvus. The FDA told Novartis earlier this year that it needed additional information on Galvus. Novartis expects a decision on Tasigna in the fourth quarter. Release

> Sucampo expects its IPO to price at $14 to $16 a share. Report

> Rosetta Genomics is expanding its Israeli research facility. Report

> U.S. researchers have identified a novel method for treating post traumatic stress disorder, raising the prospect of a new therapy for treating fear. Report

> Shinya Yamanaka, one of Japan's leading stem cell scientists, says he believes he is just months away from developing a prototype stem cell that could substitute for an embryonic stem cell in research. Report

And Finally… In a report that is sure to infuriate every researcher looking for a new job, some companies say that the struggle to find top scientific talent is harder than ever. Report

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.